Evidence map›Paper›PMID 41141552›Full record

ArticleEuropean heart journal. Case reports2025

A case report of a novel approach to the management of refractory coronary vasospasm.

Danielle Lapin, Con Arronis, Nigel Jepson

Abstract readCase Reports
In one paragraph

Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Danielle LapinCancer Centre for Children, The Children's Hospital at Westmead, Hawkesbury Rd, Westmead, NSW 2145, Australia.ORCID https://orcid.org/0009-0005-9568-1826
Con ArronisDepartment of Cardiology, Prince of Wales Hospital, High St, Randwick, NSW 2031, Australia.
Nigel JepsonDepartment of Cardiology, Prince of Wales Hospital, High St, Randwick, NSW 2031, Australia.ORCID https://orcid.org/0000-0003-4403-8273

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronary vasospasm, or vasospastic angina (VSA), is a clinical entity that can uncommonly occur in the setting of non-obstructive coronary disease. Refractory VSA can be associated with significant adverse cardiovascular events, and a paucity of evidence-based guidelines makes this a challenging clinical scenario for clinicians to treat effectively. Case summary: A 46-year-old male presenting with a 48 h history of epigastric pain with electrocardiogram changes suggestive of left anterior descending artery stenosis and angiography showing no significant obstructive disease. The patient then developed recurrent early morning chest pain with multi-territory ST elevation despite antispasm therapy with repeat angiography and optical coherence tomography showing no evidence of obstructive disease. The patient was diagnosed with idiopathic refractory coronary vasospasm and ultimately managed with corticosteroids and with a wearable cardiac defibrillator. Discussion: The case presented highlights the diagnostics challenges and treatment complexity in managing refractory coronary vasospasm in which our patient experienced a good long-term outcome despite high risk features. Steroids are infrequently used in the management of coronary vasospasm but represent a life-saving treatment option in the setting presumed inflammation. Wearable cardiac defibrillator can be used to both investigate and prevent fatal arrhythmia and should be considered in high-risk coronary vasospasm cohorts.

Indexed as

Case reportCorticosteroidsRefractory coronary vasospasmWearable cardiac defibrillator

Identifiers

PMID41141552
PMCPMC12548726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.